CME Group stock holds near record range as 2024 volumes and earnings expand
Published on 07/24/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CME Group Inc. (ISIN US12572Q1058) reported higher earnings and record trading activity in early 2024, and CME Group stock remains supported by this growth backdrop as the operator of the major US futures exchange consolidates its position in global derivatives trading.
Revenue up 3 percent in Q1 2024
According to CME Group's first quarter 2024 earnings release dated 24 April 2024, total revenue for the quarter reached $1.49 billion, an increase of 3 percent from $1.45 billion in the first quarter of 2023 as higher market data and other non-transaction revenues offset a slight decline in clearing and transaction fees. In the same period, operating income was $883 million, compared with $865 million a year earlier, highlighting the company's ability to convert incremental revenue into profit through disciplined expense control. The company reported that non-GAAP operating margin remained above 60 percent in the first quarter of 2024, reflecting the high fixed-cost nature of exchange infrastructure and the scalability of its trading platforms.
Net income attributable to CME Group for the first quarter of 2024 was $872 million, up from $770 million in the first quarter of 2023, driven by both revenue growth and higher investment income on cash collateral balances. On a per-share basis, diluted earnings per share for the quarter were $2.43 compared with $2.16 a year earlier, an increase of 12.5 percent year over year, underscoring the combined effect of higher profitability and a relatively stable share count.
Average daily volume reaches 26.4 million contracts
CME Group highlighted that first quarter 2024 average daily volume, or ADV, across its futures and options complex reached 26.4 million contracts, compared with 26.9 million contracts in the year-ago period, reflecting a slight year-on-year decline after exceptionally elevated activity in early 2023. Within that total, interest rate ADV was 15.4 million contracts in the quarter versus 16.0 million contracts in the first quarter of 2023 as short term rate volatility normalized after the banking stresses of the previous year. Equity index ADV came in at 5.2 million contracts, broadly in line with the first quarter of 2023 as investors continued to trade CME's futures and options on major US equity benchmarks.
Foreign exchange products at CME Group recorded average daily volume of 1.0 million contracts in the first quarter of 2024, modestly below the 1.1 million contracts a year earlier, while energy products posted ADV of 2.5 million contracts compared with 2.3 million contracts in the prior-year quarter as crude oil and refined product volatility attracted more hedging and speculative interest. The agricultural commodities franchise contributed average daily volume of 1.4 million contracts in the quarter, down from 1.6 million contracts a year ago as grain price volatility softened from the peaks seen in 2022 and early 2023.
More background on CME Group fundamentals
For additional context on revenue mix, margins, and recent performance, see further reports and filings linked to the ISIN US12572Q1058 and the companys investor relations page.
Dividend and capital returns remain a support
CME Group's capital return policy has long been a key element of the investment case for CME Group stock, with the company combining a regular quarterly dividend and periodic variable special dividends funded by strong free cash flow. As disclosed in its 2023 annual report, CME Group paid out $1.00 per share in regular quarterly cash dividends during the year, and it has steadily increased this regular dividend over the past decade while maintaining a conservative balance sheet. In addition, the company distributed a variable special dividend of $5.25 per share in January 2024 based on its 2023 cash generation, continuing a pattern of year-end special payments to shareholders.
Across the full year 2023, CME Group reported total revenue of $5.6 billion, up from $5.0 billion in 2022, supported by record trading volumes across several asset classes as interest rate and commodity volatility remained elevated. Net income for 2023 reached $3.0 billion compared with $2.7 billion in 2022, with diluted earnings per share of $8.25 versus $7.55 in the prior year as operating leverage amplified the impact of higher revenue on the bottom line. These figures illustrate that the company entered 2024 from a position of financial strength, providing flexibility to maintain both its regular and variable dividend framework even as market conditions evolve.
Product mix anchored by E-mini S&P 500 futures
A core product underpinning CME Group's franchise is its E-mini S&P 500 futures contract, which has become a benchmark instrument for managing exposure to the US equity market among institutional investors and active traders. The contract offers a notional exposure to the S&P 500 index in a smaller size than the full-size futures, enabling more flexible hedging and trading strategies for a broad range of market participants. Trading in E-mini S&P 500 futures contributes significantly to CME Group's equity index segment volumes and fee revenue, particularly during periods of heightened equity market volatility.
Beyond equity index products, CME Group's offerings span interest rate futures such as Eurodollar and SOFR-based contracts, foreign exchange contracts on major currency pairs, energy futures and options on crude oil, natural gas, and refined products, as well as agricultural contracts covering grains, oilseeds, livestock, and soft commodities. This diversified product set allows CME Group to capture trading and hedging flows across macroeconomic cycles, and helps smooth the impact of volume swings in any single asset class on the company's overall revenue base.
CME Group stock and valuation context
CME Group stock is listed on the Nasdaq Global Select Market under the ticker CME, and the company is a constituent of the S&P 500 index, which means it is widely held by passive and active funds tracking large-cap US equities. As of mid 2024, CME Group's market capitalization stands in the range of approximately $80 billion, reflecting investor expectations for continued steady growth in trading volumes and earnings over the medium term. The stock typically trades at a valuation premium to many traditional financial institutions, mirroring the high margins, strong cash generation, and relatively low credit risk associated with the exchange business model.
For investors, the combination of expanding derivatives usage, structurally higher demand for risk management tools, and CME Group's disciplined cost control and shareholder return policies form a set of factors that help explain why CME Group stock has held close to record levels. While future volume growth remains sensitive to macroeconomic variables such as interest rate volatility and commodity price swings, CME Group's broad product mix and high operating leverage provide a platform for incremental revenue growth to translate efficiently into earnings and cash flow.
Key data on CME Group
- Company: CME Group Inc.
- ISIN: US12572Q1058
- Ticker: NASDAQ: CME
- Trading venue: Nasdaq Global Select Market
- Market capitalization: approximately $80 billion (as of mid 2024)
- Sector / Industry: Financials / Exchanges and Data
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
